Healthtech funding in H2 2024
European Healthtech startup funding raised during H2 2024.
In H2 2024, 200 European Healthtech companies closed 202 funding rounds and raised €2.9B in equity funding (excluding debt and grants), down 36.2% versus H2 2023. Debt rounds added €40M. UK led by capital raised, and High-Tech Gründerfonds (HTGF) was the most active investor. Data as of 20 Nov 2026.
Equity funding
€2.9B
-36.2% vs H2 2023 · excl. debt & grants · +€40M debt
Funding rounds
202
-10.6% vs H2 2023
Companies
200
Top country
UK
Rank among sectors
#3
11.6% of sector funding
Debt financing
€40M
1.4% of total
Top-10 round share
44.2%
of disclosed capital
Rounds ≥ €100M
4
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, H2 2024 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jul | €425M | 31 |
| Aug | €364M | 25 |
| Sep | €367M | 39 |
| Oct | €431M | 27 |
| Nov | €407M | 40 |
| Dec | €916M | 40 |
Top countries
by € raisedHealthtech — top countries by capital, H2 2024 — interactive chart.
Data table
| Healthtech — top countries by capital, H2 2024 | |
|---|---|
| UK | €907M |
| Switzerland | €491M |
| Germany | €362M |
| Finland | €271M |
| France | €231M |
| Netherlands | €197M |
| Belgium | €136M |
| Denmark | €110M |
Stage mix
by € raisedHealthtech — stage mix, H2 2024 — interactive chart.
Data table
| Healthtech — stage mix, H2 2024 | |
|---|---|
| Other | €887M |
| Series D+ | €553M |
| Series B | €468M |
| Series C | €405M |
| Series A | €380M |
| Seed | €147M |
| Debt | €40M |
| Pre-Seed | €17M |
| Grant | €13M |
Exits & M&A
8 Acquisition · 2 Merger11 exits · €50M disclosed.
| Lamidey Noury Medical | Acquisition | Nov 2024 | €50M |
Top deals
largest disclosed rounds in H2 2024| Company | Stage | Date | Amount |
|---|---|---|---|
| Cimeio Therapeutics | Other | Dec 2024 | €282M |
| ŌURA | Series D+ | Dec 2024 | €192M |
| Flo Health | Series C | Jul 2024 | €185M |
| Caresyntax | Series C | Aug 2024 | €164M |
| Citryll | Series B | Dec 2024 | €85M |
| Agomab Therapeutics | Series D+ | Oct 2024 | €83M |
| Antag Therapeutics | Series A | Dec 2024 | €80M |
| Huma | Series D+ | Jul 2024 | €73M |
| ŌURA | Series D+ | Nov 2024 | €71M |
| Cradle | Series B | Nov 2024 | €69M |
| Nuclera | Series A | Oct 2024 | €69M |
| Neo Medical | Other | Sep 2024 | €61M |
| Oxford Nanopore Technologies | Other | Aug 2024 | €59M |
| Quanta Dialysis Technologies | Series D+ | Nov 2024 | €57M |
| Basecamp Research | Series B | Oct 2024 | €55M |
Top investors
most active in H2 2024, by deal count- High-Tech Gründerfonds (HTGF)8 deals
- Venture Kick5 deals
- IBB Ventures4 deals
- Mercia Ventures4 deals
- Novo Holdings4 deals
- Scottish Enterprise4 deals
- SFC Capital4 deals
- BGF3 deals
- Carma Fund3 deals
- Export and Investment Fund of Denmark (EIFO)3 deals